NCT02705989View on ClinicalTrials.gov

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

439

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

August 16, 2017

Study Completion Date

August 16, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BMS-986195

Specified dose on specified day

OTHER

Placebo

Specified dose on specified day

Trial Locations (1)

3004

Local Institution, Melbourne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY